Search bioRxiv⌕ Search

Biology subjects

Ghulam, M.

Publications and source records attributed to Ghulam, M..

2 recordsLinked to original sources

A DERIVED RELAXATION CONTRAST FROM SYNTHETIC MRI FOR DETECTING NETWORK MICROSTRUCTURAL VULNERABILITY

BackgroundOdor identification impairment is an early marker of Alzheimers disease (AD) that predicts memory decline, yet its underlying microstructural basis remains unclear. We hypothesized that mild cognitive impairment (MCI) involves early myelin and lipid disruption within olfactory-limbic circuits, detectable using a synthetic MRI-derived contrast that provides complementary sensitivity to myelin volume fraction (MVF). MethodsThirty-three older adults (healthy controls [HC], n = 16; mild cognitive impairment [MCI], n = 17) completed olfactory and cognitive testing and underwent 3T brain MRI using a QALAS sequence. An MVF map and synthetic FLAIR and DIR images were generated, and a FLAIR-DIR-derived metric (FD) was computed as FD = (FLAIR - DIR) / FLAIR. We investigated ROI-based group differences in olfactory-limbic gray-matter regions and associated white-matter tracts, voxel-wise regressions investigating FD-odor identification associations, and ROI-based MCI vs HC classification using cross-validated logistic regression models. ResultsCompared with HC, MCI showed significantly lower FD across olfactory-limbic gray-matter regions and white-matter pathways--including hippocampus, amygdala, orbitofrontal cortex, thalamus, and corpus callosum--whereas MVF differences were more limited. FD achieved moderate discrimination, with baseline performance comparable to MVF. Voxel-wise analyses revealed that better odor identification was associated with higher FD in the hippocampus/parahippocampal and insula; the association persisted after adjusting for voxel-wise MVF. MVF also showed significant positive voxel-wise associations with odor identification in the insula and genu of the corpus callosum. ConclusionFD is a practical, myelin- and lipid-sensitive contrast derived from routinely acquired synthetic FLAIR & DIR images that complement quantitative MVF. It captures behaviorally relevant variance beyond local myelin content and may improve detection of early olfactory-limbic microstructural changes in MCI. These findings support FD as a scalable candidate marker linking early network disruption to olfactory symptoms across the AD continuum.

neuroscience↗

"Regulation of Obesity and Fatty Liver by Moringa oleifera: Insights into Inflammatory Pathways"

Obesity and fatty liver are relatively benign states but continued inflammatory stress and its metabolic implications turn them into one of the most devastating diseases of humankind. Generally, obesity and fatty liver precede diabetes mellitus, cardiovascular problems and malignant growths. The present research aimed to explore the efficacy of methanolic extract of Moringa Olifera (Me.MO) for the management of obesity and fatty liver and related inflammatory state that prime the body for devastating effects. A series of in-vitro and in-vivo studies were employed. Data from HPLC analysis confirmed the presence of flavonoids and phenolic acids. Rats were fed on either normal diet (ND) or high fat diet (HFD and streptozocin (STZ) in the presence or absence of Me.Mo (250 mg/kg & 500 mg/kg) or metformin (70 mg/kg). Findings showed that rats received 500 mg/kg Me.MO showed a significant (p > 0.01) decrease in body weights, liver weights, and plasma glucose level. Laboratory data exhibited a significant (p < 0.05) inhibitory effect on Me.MO on pro-inflammatory mediators (IL-1B and TNF) and caused a sharp increase in anti-inflammatory cytokines levels (IL-10, IL-6 and COX-2) in all treatment groups. Histopathological analysis exhibited no structural and functional alteration in the liver and adipose tissues. Altogether, Me.MO ameliorates experimentally induced obesity accompanying fatty liver and inflammatory stress. However, further investigations are still needed to confirm the safety and efficacy of Moringa{beta} olifera (MO) for clinical application.

pharmacology and toxicology↗